Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Mount Sinai School of Medicine
Sponsor:
Collaborator:
Salix Pharmaceuticals
Information provided by (Responsible Party):
Douglas T. Dieterich, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01654939
First received: July 30, 2012
Last updated: October 24, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)